Navigation Links
Nature publishes results of gene therapy treatment in phase 1/2 beta-thalassemia study
Date:9/16/2010

ere beta-thalassemia is living without the need for transfusions over a sustained period of time," said Marina Cavazzana-Calvo, M.D., first co-author of the study and professor of hematology, University of Paris and chief of Cell and Gene Therapy Department, Necker-Enfants Malades Hospital in Paris. Salima Hacein-Bey-Abina, Ph.D., professor of immunology, University of Paris, added, "These results are not only important due to the tremendous medical need that exists for thalassemia patients around the world, but also represents a significant step forward for the field of autologous stem cell therapy as an emerging therapeutic modality."

Dr. Franoise Bernaudin, the clinical hematologist who has followed this patient since early childhood, said, "It is wonderful to see that this young man is for now free of transfusions and injections for iron chelation. He is happy to have a normal life back, and for the first time has a full-time job as a cook in a main restaurant in Paris. We are now even able to bleed him regularly to help remove toxic iron that had accumulated over the years because of blood transfusions."

The paper, titled "Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassemia," is available in the online publication of Nature at www.nature.com.

"We believe the human findings in beta-thalassemia, as well as the recently published data in Science on two patients with childhood cerebral adrenoleukodystrophy (CCALD), highlight the significant opportunity for bluebird bio's gene therapy platform to help patients with severe genetic disorders," said Nick Leschly, president and CEO of bluebird bio. "We are committed to building a world-class company in gene therapy led by outstanding people as we move aggressively forward with multiple clinical studies, including our ongoing clinical trials for the development of LentiGlobin for beta-thalassemia and our product for
'/>"/>

Contact: Dan Budwick
dan@purecommunicationsinc.com
973-271-6085
Pure Communications Inc.
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Nature study shows how molecules escape from the nucleus
2. Quantum computer a stage closer with silicon breakthrough, reports Nature journal
3. Study sheds light into the nature of embryonic stem cells
4. Muscular protein bond -- strongest yet found in nature
5. Nature parks can save species as climate changes
6. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
7. Cell Biosciences Announces Publication in Nature Medicine
8. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
9. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
10. Light-speed nanotech: Controlling the nature of graphene
11. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... SAN ANTONIO , 23 de julio de ... ADBI (ADBI o la Compañía) ha anunciado hoy ... Akron (ABIA o el Instituto), ... de ADBI, un dispositivo de terapia de señal ...   El Instituto, que tiene una ...
(Date:7/23/2014)... , July 23, 2014 ... portfolio company of Trendlines Agtech , announced ... Israel,s leading agricultural thermoplastics ... Valentis,s technology combines nanocrystalline cellulose (NCC), ... waste, with additional nanoparticles to produce highly improved ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber Inc. ... company producing sustainable chemicals, today announced that the underwriters ... their option to purchase an additional 420,000 shares ... of $12.00 per share, less underwriting discounts and ... public offering of 2,800,000 shares of common stock, ...
(Date:7/23/2014)... Shire plc (LSE: SHP, ... biopharmaceutical company, and ArmaGen, a US privately held ... collaboration agreement for AGT-182, an investigational enzyme replacement ... the central nervous system (CNS) and somatic manifestations ... collaboration strengthens Shire,s rare disease pipeline of innovative ...
Breaking Biology Technology:ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5
... Mass., March 11 Abt Associates announced it has ... United States Agency for International Development (USAID) to lead ... while protecting biodiversity in Mexico.Mexico is a member of ... 2000 mile border with the United States. USAID ...
... Pharma, Inc. (NYSE Alternext US: DDD) today reported financial ... 31, 2008. The Company will host a live ... (Eastern Daylight Time)."Last year was an important period for ... Ph.D., M.B.A. "Utilizing our unique CDT(R) platforms, we made ...
... State of Qatar to Introduce State-of-the-Art Treatments including ... the leading cancer centers in the Middle East ... Medical Systems (NYSE: VAR ) equipped ... Al Amal Hospital in Doha, Qatar, is replacing ...
Cached Biology Technology:USAID Selects Abt Associates to Lead Team in Strengthening Mexico Private Sector Competitiveness 2SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 2SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 3SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 4SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 5SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 6SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 7SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 8Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems 2Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems 3
(Date:7/23/2014)... MINNETONKA, Minn. , July 23, 2014 /PRNewswire/ ... technology company specializing in clinical study management systems, ... West , a proven life sciences industry executive ... named Chief Operating Officer (COO).  Clareece will be ... and sales growth, operational efficiency and quality product/service ...
(Date:7/23/2014)... hookworms and a protist called Blastocystis can be ... argues we should rethink our views of organisms that live ... co-author Julius Luke even ingested three developmental stages of a ... more than a year with the tapeworms, which might have ... now, he says he feels fine. , "I knew there ...
(Date:7/23/2014)... YORK, NY -- The New York Stem Cell Foundation ... to develop stem cell resources to investigate and explore ... Batten disease, a fatal illness affecting children. , NYSCF ... from skin samples of young people affected by juvenile ... cell lines are produced by artificially "turning back the ...
Breaking Biology News(10 mins):MedNet Appoints Clareece West As Chief Operating Officer 2Intestinal parasites are 'old friends,' researchers argue 2Intestinal parasites are 'old friends,' researchers argue 3NYSCF partners with Beyond Batten Disease Foundation to fight juvenile Batten disease 2NYSCF partners with Beyond Batten Disease Foundation to fight juvenile Batten disease 3
... in the United States will receive a diagnosis of breast ... cause of cancer-related death in women. Now a new test ... patient. "Our research shows that there is a subset ... at all, other than a lumpectomy," explains Philip Bernard, M.D., ...
... free, two-day colloquium begins February 12, 2009 with the ... originator of the modern theory of evolution of species ... foundation of all modern biology. The invited speakers provide ... and empirical research. As such, the symposium emphasizes how ...
... direct chemical modifications to specific sites on recombinant proteins ... pharmaceutical industry has been developed by Carolyn Bertozzi ... Lawrence Berkeley National Laboratory and the University of California ... diabetes, can be made in bacterial systems like ...
Cached Biology News:New test for breast cancer will help guide treatment choices 2Darwin's legacy in 21st century biology 2Tailor-made recombinant proteins in mammals 2Tailor-made recombinant proteins in mammals 3Tailor-made recombinant proteins in mammals 4
... Phosphothioate (PTO) oligonucleotides: PTOs are ... the phosphate backbone is replaced by a ... against nuclease degradation. PTOs are available as ... are phosphothioates Oligonucleotides with thio-caps ...
The mini vertical flow workbench is designed to perform PCR protocols in a particle-free environment. The built-in UV light ensures the elimination of any nucleic acid to avoid cross-contamination....
... For microsatellite research, the 4300 System ... genotyping automation software available. SagaGT automates electrophoresis, ... band sizes, and allele scoring. ,Saga GT ... LI-COR. Saga 1.0 (Unix) was initially developed ...
MOUSE ANTI GTP BINDING PROTEIN...
Biology Products: